Faculty Opinions recommendation of Long-term survival in amyotrophic lateral sclerosis: a population-based study.

2017 ◽  
Author(s):  
Ammar Al-Chalabi
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Population Based ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival ◽  
Lateral Sclerosis

Long-term survival in amyotrophic lateral sclerosis: A population-based study

2014 ◽  
Vol 75 (2) ◽  
pp. 287-297 ◽  
Author(s):  
Elisabetta Pupillo ◽  
Paolo Messina ◽  
Giancarlo Logroscino ◽  
Ettore Beghi ◽  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Population Based ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival ◽  
Lateral Sclerosis

scholarly journals Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

2021 ◽  
Vol 14 (8) ◽  
pp. 705
Author(s):  
Hideki Houzen ◽  
Takahiro Kano ◽  
Kazuhiro Horiuchi ◽  
Masahiro Wakita ◽  
Azusa Nagai ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Rank Test ◽  
Positive Pressure ◽  
Control Group ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
Lateral Sclerosis

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.

Long-term Survival of Patients With Anorexia Nervosa: A Population-Based Study in Rochester, Minn

2003 ◽  
Vol 78 (3) ◽  
pp. 278-284 ◽  
Author(s):  
Sergio R. Korndörfer ◽  
Alexander R. Lucas ◽  
Vera J. Suman ◽  
Cynthia S. Crowson ◽  
Lois E. Krahn ◽  
...  
Keyword(s):  
Anorexia Nervosa ◽  
Population Based ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival

Long-term survival in amyotrophic lateral sclerosis after stem cell transplantation into the frontal motor cortex

Cytotherapy ◽  
2016 ◽  
Vol 18 (6) ◽  
pp. 806-808 ◽  
Author(s):  
Héctor R. Martínez ◽  
María Teresa González-Garza ◽  
Jorge Moreno-Cuevas ◽  
César E. Escamilla-Ocañas ◽  
Juan Miguel Tenorio-Pedraza ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Stem Cell ◽  
Motor Cortex ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Term Survival ◽  
Long Term Survival ◽  
Lateral Sclerosis

Long-Term Survival of People with Unprovoked Seizures: A Population-Based Study

Epilepsia ◽  
1998 ◽  
Vol 39 (1) ◽  
pp. 89-92 ◽  
Author(s):  
Elias Olafsson ◽  
W. Allen Hauser ◽  
Gunnar Gudmundsson
Keyword(s):  
Population Based ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival

scholarly journals Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival

2018 ◽  
Vol 150 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Jill H. Tseng ◽  
Alessia Aloisi ◽  
Yukio Sonoda ◽  
Ginger J. Gardner ◽  
Oliver Zivanovic ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radical Surgery ◽  
Population Based ◽  
Term Survival ◽  
Population Based Study ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document